I'm LongbridgeAI, I can summarize articles.Iambic Therapeutics (IAM.US) surged more than 8% during regular trading to $14.48.
The stock is down 12.25% from its first-day open and sits 50.83% above its 52-week low of US$9.600.
The Nasdaq Composite is down 1.28% over the past five sessions and up 7.77% year to date.
Iambic presented updated Phase 1/1b clinical trial results for its HER2 inhibitor IAM1363 at the European Society for Medical Oncology congress, showing durable responses and good tolerability in heavily pretreated patients with HER2-mutated advanced cancer.
Based on public media reports. AI-generated; not investment advice.
